In March 2025, the global pharmaceutical sector witnessed a surge of innovation where technology deeply integrates with clinical needs, spanning key areas.

In February 2025, the global pharmaceutical industry witnessed a series of milestone post-marketing collaboration deals.

Our analysis of February data reveals key trends in global clinical-stage biopharmaceutical financing.

In February 2025, the global biopharmaceutical industry remains active in clinical-stage drug financing and collaboration activities.

Our analysis of February data reveals key trends in global preclinical-stage biopharmaceutical financing.

As global healthcare continues to demand innovative therapies, February 2025 has emerged as a critical period witnessing the robust growth of the biopharmaceutical sector.

February 2025 brought a wave of exciting news for innovators in the global healthcare industry.

Hansoh Pharma entered into a strategic collaboration with Merck & Co. worth over $2 billion, granting Merck the exclusive global license for its investigational GLP-1 receptor agonist, HS-10535.

February 2025 witnessed a wave of mergers and acquisitions in the global biopharmaceutical sector.

February saw the first approvals of several important new drugs.

In January 2025, the global pharmaceutical industry's investment and licensing activities demonstrated a strong interest in novel treatment methods and technologies.

In January 2025, the pharmaceutical collaborations and transactions showcased a diversified trend of development, ranging from multinational pharmaceutical corporations to startup biotech enterprises.